Propranolol in Angiosarcoma

Summary

This is a window opportunity study of propranolol in patients with angiosarcoma. The aim of this study is to prospectively evaluate the activity of propranolol in the clinical setting as monotherapy, where the neoadjuvant setting provides a good opportunity to rapidly evaluate both the clinical response and histological response, without a significant delay in anti-cancer treatment.

Timeline

Start

2019-12-27

Primary completion

2023-10-30

Completion

2023-10-30

Drugs

Indications